Upon tumor rechallenge with CT26 cells, none of these previously treated mice displayed tumor growth (Fig. 6C), demonstrating that the combination of TransCon TLR7/8 Agonist with systemic immunotherapy promoted the functional generation of a robust anti-tumor immune memory response. Here, TLR7 is linked to neoplasm.